Citations

Clear

426 citation(s) found for "ST, Reza".

Disproportionately high aortic valve calcium scores in atrial fibrillation: implications for transcatheter aortic valve replacement
Masson, Rajeev , Holmes, David R. , Klanderman, Molly, Abraham, Bishoy , Morsy, Mahmoud , Fortuin, F. David , Sweeney, John P., Sell-Dotten, Kristen, Alsidawi, Said , Alsidawi, Said , Nkomo, Vuyisile T. , Pislaru, Sorin V. , Arsanjani, Reza , Chao, Chieh‐Ju

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | April 26, 2024 | Volume: 25 | Issue: 9 | Pages: 1264-1275

10.1093/ehjci/jeae113 | PMID 38669204 Get It

Abstract Aims Doppler mean gradient (MG) can underestimate aortic stenosis (AS) severity in patients with atrial fibrillation (AF) compared with patients with sinus rhythm (SR), potentially delaying intervention in AF. This study compared outcomes in patients with AF and SR following transcatheter aortic valve replacement (TAVR) and investigated delay in TAVR based on computed tomography aortic valve calcium score (AVCS). Methods and results Patients who underwent TAVR from 2013 to 2017 for native valve severe AS were identified from an institutional database. Baseline characteristics and overall survival were compared between those with SR and AF. There were 820 patients (mean age 81 years; 41.6% females) included in this study. AF was present in 356 patients. Patients with AF were older (82.2 vs. 80.5, P = 0.003) and had a lower MG compared with patients with SR (42.0 vs. 44.9, P = 0.002) with similar indexed aortic valve area (0.4 vs. 0.4, P = 0.17). Median AVCS was higher in AF (males: AF 2850.0 vs. SR 2561.0, P = 0.044; females: AF 1942.0 vs. SR 1610.5, P = 0.025). Projected AVCS, assuming the same age of diagnosis, was similar between AF and SR. Median survival post-TAVR was worse in AF compared with SR (3.2 vs. 5.4 years, log rank P < 0.001). AF, lower MG, higher right ventricular systolic pressure, dialysis, diabetes, and significant tricuspid regurgitation were associated with higher mortality (P < 0.05 for all). Conclusion Older age and higher AVCS in patients with AF compared with those with SR suggest that AS was both underestimated and more advanced at TAVR referral.
Abstract 14356: Trends of Acute Myocardial Infarction Mortality Rates in the United States From 1999-2019: A Retrospective Study
Venepally, Nithin R. , Dang, Thao, Sierra, Juan, Bakhati, Bibek, Sai, Mungara, Jha, Govind Kumar , Agasthi, Pradyumna , Matute, Carlos , Khetarpal, Banveet Kaur , Jha, Govind, Arsanjani, Reza

Mayo Clinic

Circulation | April 23, 2024 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.14356 Get It

Introduction: In the current study, we examined the temporal trends in mortality across gender, race, and 10-year age groups over last two-decades. Methods: We conducted a retrospective population-based study using Centers for Disease Control and Prevention database. Subjects with underlying cause of death from AMI were identified using validated ICD10 codes. Age adjusted mortality rates were calculated for gender and race whereas crude rates were calculated for 10-year age group. Using Poisson regression, we estimated the rate ratio between race/ethnicity pairs adjusting for age and sex in order to analyze temporal trend. Results: We identified 2,709,173 subjects with reported underlying cause of death as AMI between January-2000 to December-2019 of which 54.7% were males (n=1,483,163). The age adjusted mortality rate per 100,000 was higher in males compared to females (52.4% vs 30.7%, OR: 1.66 [1.45-1.89]). Among ethnicities African American (AA) population had the highest age adjusted mortality rate per 100,000 [Table 1]. As expected, age group >85 years had the highest mortality rate per 100,000 constituting 30% of total deaths (78% of total deaths were noted in >65yr age group). AMI age adjusted mortality rates/100,000 showed significant decline across gender and race with highest decline in female population (66.5% decline). Highest percentage decline in mortality was noted in AA female population (68.2%) whereas in males it was the white population (62%). In females, highest percentage decline in mortality was noted in 75-84 age-group (70%) while it was >85 age-group (67%) in males. Conclusion: Over last two decades there has been a significant decline in AMI mortality rates across gender and race. AA continue to have higher age adjusted mortality rate among both male and female population (38% and 22% respectively). Further studies are needed to identify and provide targeted prevention and intervention strategies in high-risk populations.
Abstract 16999: Effect of Positional Echocardiogram on Right Sided Hemodynamics in Pectus Excavatum Patients vs. Healthy Adults
Pulivarthi, Venkata Siva Krishna Kumar, Jaroszewski, Dawn E. , Mookadam, Farouk , Arsanjani, Reza

Mayo Clinic

Circulation | April 23, 2024 | Volume: 138 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.138.suppl_1.16999 Get It

Introduction: Pectus excavatum (PE) is the most common anterior chest wall deformity with dorsal deviation into the thoracic cavity. Depending on the severity, PE can cause minor cosmetic problem to significant cardiac compression in severe cases. This compression most frequently affects right heart chambers causing symptoms such as dyspnea, palpitations, fatigue, exercise intolerance, and difficulty with keeping up with peers. Previously, we reported the change in these symptoms with positon associated with change in right heart hemodynamics. Further, we are comparing the changes in right heart hemodynamics with position in pectus patients to normal healthy adults. Methods: A prospective cohort of 40 pectus excavatum patients (mean Haller index: 5.4±2) undergoing evaluation at Mayo clinic underwent 2-D transthoracic echo (TTE) with Doppler assessment of Right Ventricular Outflow Tract (RVOT) Velocity Time Integral (VTI). A cohort of 8 healthy adults without chest wall abnormality who had clinically indicated echocardiogram was used as control (Table). Additional assessment of the RVOT VTI was performed in sitting position in either group. A two-sample t-test was performed to assess significance between cohorts. Results: There is a significant difference in RVOT VTI between case and control cohorts in both supine and sitting positions (p=0.03 & p=0.001 respectively). Also, there is a significant decrease in RVOT VTI from supine to sitting position in PE patients compared to healthy adults (Table). Conclusion: This is the 1 st prospective cohort study in PE patients vs healthy adults showing the feasibility and utility of dynamic echocardiography in assessing the right ventricular hemodynamics. This study demonstrates a significant decrease in right sided hemodynamic changes with change in position in patients with PE which might explain their symptoms.
Stripping versus ligation of vas deferens in microscopic denervation of spermatic cord in men with chronic orchialgia: A multicenter study
El‐Achkar, Adnan , Hammad, Muhammed , Barham, David , Service, C Austin, Hsieh, Tung- Chin, Mills, Jesse N. , Ziegelmann, Matthew , Smith, Ryan P. , Bernie, Helen L. , Egert, Melissa , Gross, Kelli, Pastuszak, Alex, Hotaling, James M. , Yafi, Faysal A. , Hammad, Muhammed A M , Patel, Darshan P. , Kianian, Reza , Eleswarapu, Sriram Venkata , Bryk, Darren J. , Raheem, Omer A. , Fendereski, Kiarad

Mayo Clinic

Andrology | April 19, 2024 | Volume: 13 | Issue: 2 | Pages: 268-274

10.1111/andr.13650 | PMID 38639020 Get It

AbstractBackgroundMicrodenervation of the spermatic cord (MSCD) is an effective treatment modality for men with intractable scrotal content pain. For patients not interested in preserving fertility, some centers advocate ligation of the vas during denervation, while others prefer stripping of the vas deferens to preserve the vasal artery, hence preserving vasculature to the testis and possibly decreasing post‐operative congestion pain.ObjectiveTo compare outcomes of patients with chronic orchialgia, who underwent MSCD by either stripping or ligating the vas deferens.Materials and methodsA retrospective chart review of 85 patients who underwent MSCD from 2017–2023 was performed. Patients’ demographics including history of prior surgical procedures were recorded. Response to surgery was evaluated as either complete resolution of pain, partial resolution of pain, or no improvement in pain.ResultsEighty‐five patients underwent MSCD with a median (interquartile range, IQR) age of 36 (25.5–46.5) years and median duration of pain of 16 (6–31) months. Thirty‐seven patients underwent stripping of vas, while 48 underwent ligation of vas during MSCD. Median follow up was 12 months. Twenty‐one (43.5%) patients had prior inguinal scrotal surgery in the ligation group compared to 5 (13.5%) in the stripping group, p = 0.003. The etiology of pain was similar between the groups. The response to MSCD between the two groups was similar, 67.6% of patients who underwent stripping had complete resolution of pain versus 66.7% of those who had ligation (p = 0.968), with similar rates of post‐operative complications (p‐value = 0.132).ConclusionsIn men with intractable chronic scrotal content pain with no interest in preserving fertility, ligation, or stripping of the vas deferens yields similar outcomes with regard to pain resolution. Both techniques are safe with no reports of any testicular atrophy.
Multi-Modality Imaging in Vasculitis
Allam, Mohamed , Ali, Nima Baba , Mahmoud, Ahmed , Scalia, Isabel G. , Farina, Juan M. , Abbas, Mohammed Tiseer , Pereyra, Milagros , Kamel, Moaz, Awad, Kamal A., Wang, Yuxiang , Barry, Timothy , Huang, Steve S. , Yang, Ming , Jokerst, Clinton, Martinez, Felipe , Arsanjani, Reza , Awad, Kamal , Allam, Mohamed N , Baba Ali, Nima, Mahmoud, Ahmed K , Kamel, Moaz A, Nguyen, Ba D. , Martinez, Felipe , Arsanjani, Reza , Farina, Juan M , Pereyra, Milagros , Scalia, Isabel G , Abbas, Mohammed Tiseer , Awad, Kamal

Mayo Clinic

Diagnostics | April 18, 2024 | Volume: 14 | Issue: 8 | Pages: 838

10.3390/diagnostics14080838 | PMID 38667483 Get It

Systemic vasculitides are a rare and complex group of diseases that can affect multiple organ systems. Clinically, presentation may be vague and non-specific and as such, diagnosis and subsequent management are challenging. These entities are typically classified by the size of vessel involved, including large-vessel vasculitis (giant cell arteritis, Takayasu’s arteritis, and clinically isolated aortitis), medium-vessel vasculitis (including polyarteritis nodosa and Kawasaki disease), and small-vessel vasculitis (granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis). There are also other systemic vasculitides that do not fit in to these categories, such as Behcet’s disease, Cogan syndrome, and IgG4-related disease. Advances in medical imaging modalities have revolutionized the approach to diagnosis of these diseases. Specifically, color Doppler ultrasound, computed tomography and angiography, magnetic resonance imaging, positron emission tomography, or invasive catheterization as indicated have become fundamental in the work up of any patient with suspected systemic or localized vasculitis. This review presents the key diagnostic imaging modalities and their clinical utility in the evaluation of systemic vasculitis.
How Artificial Intelligence Can Enhance the Diagnosis of Cardiac Amyloidosis: A Review of Recent Advances and Challenges
Kamel, Moaz, Abbas, Mohammed Tiseer , Kanaan, Christopher , Awad, Kamal A., Ali, Nima Baba , Scalia, Isabel G. , Farina, Juan M. , Pereyra, Milagros , Mahmoud, Ahmed , Steidley, D. Eric , Rosenthal, Julie , Arsanjani, Reza , Awad, Kamal , Kamel, Moaz A, Kanaan, Christopher N , Baba Ali, Nima, Mahmoud, Ahmed K , Arsanjani, Reza , Farina, Juan M , Pereyra, Milagros , Scalia, Isabel G , Abbas, Mohammed Tiseer , Awad, Kamal

Mayo Clinic

Journal of Cardiovascular Development and Disease | April 15, 2024 | Volume: 11 | Issue: 4 | Pages: 118

10.3390/jcdd11040118 | PMID 38667736 Get It

Cardiac amyloidosis (CA) is an underdiagnosed form of infiltrative cardiomyopathy caused by abnormal amyloid fibrils deposited extracellularly in the myocardium and cardiac structures. There can be high variability in its clinical manifestations, and diagnosing CA requires expertise and often thorough evaluation; as such, the diagnosis of CA can be challenging and is often delayed. The application of artificial intelligence (AI) to different diagnostic modalities is rapidly expanding and transforming cardiovascular medicine. Advanced AI methods such as deep-learning convolutional neural networks (CNNs) may enhance the diagnostic process for CA by identifying patients at higher risk and potentially expediting the diagnosis of CA. In this review, we summarize the current state of AI applications to different diagnostic modalities used for the evaluation of CA, including their diagnostic and prognostic potential, and current challenges and limitations.
Downregulation of protein phosphatase 2Aα in asthmatic airway smooth muscle
Reza, Mohammad Irshad , Pabelick, Christina M. , Britt, Rodney D. , Prakash, Y. S. , Sathish, Venkatachalem , Kumar, Ashish , Pabelick, Christina M , Britt, Rodney D , Prakash, Y S , Sathish, Venkatachalem , Kumar, Ashish

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | March 26, 2024 | Volume: 326 | Issue: 5 | Pages: L651-L659

10.1152/ajplung.00050.2024 | PMID 38529552 Get It

This novel study deciphered the expression and function of protein phosphatase 2Aα (PP2Aα) in airway smooth muscle (ASM) during asthma and/or inflammation. We showed robust expression of PP2Aα in human ASM while its downregulation in asthmatic ASM. Similarly, we demonstrated reduced PP2Aα expression in ASM exposed to proinflammatory cytokines. PP2Aα activation inhibited bronchoconstriction of isolated mouse bronchi. In addition, we unveiled that PP2Aα activation inhibits the intracellular calcium release and myosin light chain phosphorylation in human ASM.
Kisspeptin/KISS1R Signaling Modulates Human Airway Smooth Muscle Cell Migration
Balraj, Premanand , Ambhore, Nilesh Sudhakar , Ramakrishnan, Y. , Borkar, Niyati A. , Banerjee, Priyanka , Reza, Mohammad Irshad , Varadharajan, S. , Kumar, Ashish , Pabelick, Christina M. , Prakash, Y. S. , Sathish, Venkatachalem , Ramakrishnan, Yogaraj S , Varadharajan, Subashini , Prakash, Y S , Sathish, Venkatachalem , Pabelick, Christina M , Banerjee, Priyanka

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | March 21, 2024 | Volume: 70 | Issue: 6 | Pages: 507-518

10.1165/rcmb.2023-0469oc | PMID 38512807 Get It

Abstract Airway remodeling is a cardinal feature of asthma, associated with increased airway smooth muscle (ASM) cell mass and upregulation of extracellular matrix deposition. Exaggerated ASM cell migration contributes to excessive ASM mass. Previously, we demonstrated the alleviating role of Kp (kisspeptin) receptor (KISS1R) activation by Kp-10 in mitogen (PDGF [platelet-derived growth factor])-induced human ASM cell proliferation in vitro and airway remodeling in vivo in a mouse model of asthma. Here, we examined the mechanisms by which KISS1R activation regulates mitogen-induced ASM cell migration. KISS1R activation using Kp-10 significantly inhibited PDGF-induced ASM cell migration, further confirmed using KISS1R shRNA. Furthermore, KISS1R activation modulated F/G actin dynamics and the expression of promigration proteins like CDC42 (cell division control protein 42) and cofilin. Mechanistically, we observed reduced ASM RhoA-GTPAse with KISS1R activation. The antimigratory effect of KISS1R was abolished by PKA (protein kinase A)-inhibitory peptide. Conversely, KISS1R activation significantly increased cAMP and phosphorylation of CREB (cAMP-response element binding protein) in PDGF-exposed ASM cells. Overall, these results highlight the alleviating properties of Kp-10 in the context of airway remodeling.
Cardiac Allograft Vasculopathy: Challenges and Advances in Invasive and Non-Invasive Diagnostic Modalities
Kamel, Moaz, Scalia, Isabel G. , Badr, Amro , Ali, Nima Baba , Farina, Juan M. , Pereyra, Milagros , Abbas, Mohammed Tiseer , Mahmoud, Ahmed , Scott, Robert L. , Steidley, D. Eric , Rosenthal, Julie , LeMond, Lisa , Hardaway, Brian , Barry, Timothy , Yang, Ming , Jokerst, Clinton, Arsanjani, Reza , Kamel, Moaz A, Badr, Amro T , Baba Ali, Nima, Mahmoud, Ahmed K , Steidley, David E, Rosenthal, Julie L , Lemond, Lisa M , Hardaway, Brian W, Barry, Timothy , Arsanjani, Reza , Farina, Juan M , Pereyra, Milagros , Scalia, Isabel G , Abbas, Mohammed Tiseer , Sell‐Dottin, Kristen , Chao, Chieh‐Ju

Mayo Clinic

Journal of Cardiovascular Development and Disease | March 21, 2024 | Volume: 11 | Issue: 3 | Pages: 95

10.3390/jcdd11030095 | PMID 38535118 Get It

Cardiac allograft vasculopathy (CAV) is a distinct form of coronary artery disease that represents a major cause of death beyond the first year after heart transplantation. The pathophysiology of CAV is still not completely elucidated; it involves progressive circumferential wall thickening of both the epicardial and intramyocardial coronary arteries. Coronary angiography is still considered the gold-standard test for the diagnosis of CAV, and intravascular ultrasound (IVUS) can detect early intimal thickening with improved sensitivity. However, these tests are invasive and are unable to visualize and evaluate coronary microcirculation. Increasing evidence for non-invasive surveillance techniques assessing both epicardial and microvascular components of CAV may help improve early detection. These include computed tomography coronary angiography (CTCA), single-photon emission computed tomography (SPECT), positron emission tomography (PET), and vasodilator stress myocardial contrast echocardiography perfusion imaging. This review summarizes the current state of diagnostic modalities and their utility and prognostic value for CAV and also evaluates emerging tools that may improve the early detection of this complex disease.
Role of Genetics in Diagnosis and Management of Hypertrophic Cardiomyopathy: A Glimpse into the Future
Abbas, Mohammed Tiseer , Ali, Nima Baba , Farina, Juan M. , Mahmoud, Ahmed , Pereyra, Milagros , Scalia, Isabel G. , Kamel, Moaz, Barry, Timothy , Lester, Steven J., Cannan, Charles R., Mital, Rohit , Wilansky, Susan , Freeman, William K., Alsidawi, Said , Arsanjani, Reza , Baba Ali, Nima, Kamel, Moaz A, Alsidawi, Said , Arsanjani, Reza , Farina, Juan M , Pereyra, Milagros , Mahmoud, Ahmed K , Scalia, Isabel G , Abbas, Mohammed Tiseer , Chao, Chieh‐Ju

Mayo Clinic

Biomedicines | March 19, 2024 | Volume: 12 | Issue: 3 | Pages: 682

10.3390/biomedicines12030682 | PMID 38540296 Get It

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. It follows an autosomal dominant inheritance pattern in most cases, with incomplete penetrance and heterogeneity. It is familial in 60% of cases and most of these are caused by pathogenic variants in the core sarcomeric genes (MYH7, MYBPC3, TNNT2, TNNI3, MYL2, MYL3, TPM1, ACTC1). Genetic testing using targeted disease-specific panels that utilize next-generation sequencing (NGS) and include sarcomeric genes with the strongest evidence of association and syndrome-associated genes is highly recommended for every HCM patient to confirm the diagnosis, identify the molecular etiology, and guide screening and management. The yield of genetic testing for a disease-causing variant is 30% in sporadic cases and up to 60% in familial cases and in younger patients with typical asymmetrical septal hypertrophy. Genetic testing remains challenging in the interpretation of results and classification of variants. Therefore, in 2015 the American College of Medical Genetics and Genomics (ACMG) established guidelines to classify and interpret the variants with an emphasis on the necessity of periodic reassessment of variant classification as genetic knowledge rapidly expands. The current guidelines recommend focused cascade genetic testing regardless of age in phenotype-negative first-degree relatives if a variant with decisive evidence of pathogenicity has been identified in the proband. Genetic test results in family members guide longitudinal clinical surveillance. At present, there is emerging evidence for genetic test application in risk stratification and management but its implementation into clinical practice needs further study. Promising fields such as gene therapy and implementation of artificial intelligence in the diagnosis of HCM are emerging and paving the way for more effective screening and management, but many challenges and obstacles need to be overcome before establishing the practical implications of these new methods.